As the emergence of antibiotic resistance has increased, there has been a concurrent decline in the discovery and development of new classes of antibiotics. Fishwick and colleagues explore the possibility that structure-based drug design will plug this hole in the antimicrobial pipeline.
- Katie J. Simmons
- Ian Chopra
- Colin W. G. Fishwick